Systemic Lupus Clinical Trials

224 recruitingLast updated: May 21, 2026

There are 224 actively recruiting systemic lupus clinical trials across 64 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Beijing, Beijing Municipality, China, Beijing, China. Updated daily from ClinicalTrials.gov.


Systemic Lupus Trials at a Glance

224 actively recruiting trials for systemic lupus are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Phase 1 with 92 trials, with the heaviest enrollment activity in New York, Beijing, and Beijing. Lead sponsors running systemic lupus studies include The Children's Hospital of Zhejiang University School of Medicine, AstraZeneca, and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Browse systemic lupus trials by phase

About Systemic Lupus Clinical Trials

Looking for clinical trials for Systemic Lupus? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 224 trials

Recruiting

Anifrolumab Malignancy and Serious Infections Study

Systemic Lupus Erythematosus
AstraZeneca3,195 enrolled4 locationsNCT07000110
Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

MelanomaRheumatoid ArthritisAnkylosing Spondylitis+10 more
M.D. Anderson Cancer Center125 enrolled1 locationNCT04751396
Recruiting
Phase 1

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

SLESLE (Systemic Lupus)
Cullinan Therapeutics Inc.24 enrolled17 locationsNCT06613360
Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

dry eye syndromeSystemic Lupus Erythematosus
AbbVie36 enrolled7 locationsNCT06977724
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled58 locationsNCT07175285
Recruiting
Phase 1Phase 2

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies (Shanghai) Co., Ltd.118 enrolled2 locationsNCT06530849
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled9 locationsNCT07363590
Recruiting
Phase 2

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Systemic Lupus ErythematosusLupusLupus Nephritis
Hoffmann-La Roche30 enrolled15 locationsNCT07598396
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled227 locationsNCT06617325
Recruiting
Not Applicable

Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
University Hospital, Bordeaux120 enrolled1 locationNCT07260942
Recruiting
Phase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled134 locationsNCT07409181
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 4

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Systemic Lupus Erythematosus
AstraZeneca16 enrolled1 locationNCT06594068
Recruiting

AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity

Systemic Lupus Erythematosus Disease
Sohag University200 enrolled1 locationNCT07043153
Recruiting
Phase 2

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Guangdong Hengrui Pharmaceutical Co., Ltd248 enrolled2 locationsNCT07299422
Recruiting
Phase 1

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Hoffmann-La Roche70 enrolled24 locationsNCT05835986
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled5 locationsNCT07332481
Recruiting
Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled54 locationsNCT06570798
Recruiting
Phase 3

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Systemic Lupus Erythematosus
AstraZeneca100 enrolled98 locationsNCT05835310